Search company, investor...

Trellis Bioscience

trellisbio.com

Founded Year

1998

Stage

Grant - II | Alive

Total Raised

$41.64M

Last Raised

$3.2M | 3 yrs ago

About Trellis Bioscience

Trellis Bioscience provides health care products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments.

Headquarters Location

702 Marshall Street Suite 614

Redwood City, California, 94063,

United States

Missing: Trellis Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Trellis Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Trellis Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Trellis Bioscience is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Trellis Bioscience Patents

Trellis Bioscience has filed 27 patents.

The 3 most popular patent topics include:

  • Immunology
  • Monoclonal antibodies
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/5/2019

2/15/2022

Influenza, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system

Grant

Application Date

11/5/2019

Grant Date

2/15/2022

Title

Related Topics

Influenza, Monoclonal antibodies, Immunology, Clusters of differentiation, Immune system

Status

Grant

Latest Trellis Bioscience News

Sinusitis Drug Pipeline Insight Report 2022: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, & Impact of Drugs - ResearchAndMarkets.com

Sep 12, 2022

September 12, 2022 08:43 AM Eastern Daylight Time This "Sinusitis - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. A detailed picture of the Sinusitis pipeline landscape is provided which includes the disease overview and Sinusitis treatment guidelines. The assessment part of the report embraces, in depth Sinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Sinusitis. In the coming years, the Sinusitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies and academics that are working to assess challenges and seek opportunities that could influence Sinusitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. A detailed portfolio of major pharma players who are involved in fueling the Sinusitis treatment market. Several potential therapies for Sinusitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Sinusitis market size in the coming years. This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Sinusitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. Sinusitis Emerging Drugs Chapters This segment of the Sinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Sinusitis Emerging DrugsGLS-1200: GeneOne Life Science GLS-1200 nasal spray stimulates multiple bitter taste receptors (TAS2Rs) on ciliated nasal epithelial cells to produce nitric oxide as part of the innate immune system. Nitric oxide has generalized anti-microbial activity in the upper respiratory tract. Currently, it is in Phase II stage of clinical trial evaluation to treat chronic Sinusitis. LYR-210: Lyra Therapeutics Lyra's lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra's XTreoT platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naive CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients. Currently, it is in Phase III stage of clinical trial evaluation to treat chronic rhinosinusitis. TRL 1068: TRELLIS BIOSCIENCE Trellis Bioscience has used its CellSpot Technology to identify a high-affinity and broad-spectrum native human antibody, TRL1068, which targets and disintegrates bacterial biofilm. Biofilm is a physiological factor promoting drug resistance in most clinically relevant multi-drug-resistant bacteria species, both gram positive and gram negative. Biofilm is also implicated as a factor promoting Alzheimer's pathogenesis. Currently, it is in Phase I stage of clinical trial evaluation to treat Chronic Rhinosinusitis with Nasal Polyps. Sinusitis: Therapeutic Assessment This segment of the report provides insights about the different Sinusitis drugs segregated based on following parameters that define the scope of the report. Major Players in Sinusitis There are approx. 15+ key companies which are developing the therapies for Sinusitis. The companies which have their Sinusitis drug candidates in the most advanced stage, i.e. phase III include, Lyra Therapeutics. PhasesThe report covers around 20+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration

Trellis Bioscience Frequently Asked Questions (FAQ)

  • When was Trellis Bioscience founded?

    Trellis Bioscience was founded in 1998.

  • Where is Trellis Bioscience's headquarters?

    Trellis Bioscience's headquarters is located at 702 Marshall Street, Redwood City.

  • What is Trellis Bioscience's latest funding round?

    Trellis Bioscience's latest funding round is Grant - II.

  • How much did Trellis Bioscience raise?

    Trellis Bioscience raised a total of $41.64M.

  • Who are the investors of Trellis Bioscience?

    Investors of Trellis Bioscience include CARB-X, Easton Capital, New Science Ventures, Qualifying Therapeutic Discovery Project, Morgenthaler Ventures and 8 more.

  • Who are Trellis Bioscience's competitors?

    Competitors of Trellis Bioscience include Oligomerix, Array Biopharma, Threshold Pharmaceuticals, Cellerant Therapeutics, Tau Therapeutics and 12 more.

Compare Trellis Bioscience to Competitors

D
Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

B
Bionovo

Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company's strategy is to develop new drugs that it derives from natural substances used therapeutically in non-western medical practice. Bionovo's first drug is entering phase II clinical testing for menopause, its second has completed phase I clinical testing for cancer, and these are followed by more than forty additional drug candidates that the company believes should provide Bionovo with a sustainable development pipeline of new chemical entities and botanicals.

A
Altair Therapeutics

Altair Therapeutics is a biotechnology company focused on the discovery, development and commercialization of antisense drugs for respiratory conditions.

M
Mimetica

Mimetica is a Brisbane-based biotechnology company which has developed a class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.